IT1270662B - Antagonista della interleuchina-1 - Google Patents

Antagonista della interleuchina-1

Info

Publication number
IT1270662B
IT1270662B ITMI942097A ITMI942097A IT1270662B IT 1270662 B IT1270662 B IT 1270662B IT MI942097 A ITMI942097 A IT MI942097A IT MI942097 A ITMI942097 A IT MI942097A IT 1270662 B IT1270662 B IT 1270662B
Authority
IT
Italy
Prior art keywords
antagonist
new
interleuchin
prophylactic
codes
Prior art date
Application number
ITMI942097A
Other languages
English (en)
Inventor
Francesco Colotta
Maria Muzio
Alberto Mantovani
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of ITMI942097A0 publication Critical patent/ITMI942097A0/it
Priority to ITMI942097A priority Critical patent/IT1270662B/it
Priority to US08/476,860 priority patent/US5739282A/en
Priority to AU38417/95A priority patent/AU701471C/en
Priority to PCT/EP1995/004023 priority patent/WO1996012022A1/en
Priority to CNB951956647A priority patent/CN1224707C/zh
Priority to AT95936482T priority patent/ATE303439T1/de
Priority to CNB200510053993XA priority patent/CN100363053C/zh
Priority to RU97107461/13A priority patent/RU2193064C2/ru
Priority to HK98101565.6A priority patent/HK1002659B/xx
Priority to CA002202470A priority patent/CA2202470C/en
Priority to DE69534419T priority patent/DE69534419T2/de
Priority to JP8512932A priority patent/JPH10509306A/ja
Priority to DK95936482T priority patent/DK0786002T3/da
Priority to ES95936482T priority patent/ES2243942T3/es
Priority to EP95936482A priority patent/EP0786002B1/en
Priority to KR1019970701931A priority patent/KR100237936B1/ko
Priority to PT95936482T priority patent/PT786002E/pt
Priority to MX9702616A priority patent/MX9702616A/es
Priority to EE9700090A priority patent/EE03697B1/xx
Priority to BR9509317A priority patent/BR9509317A/pt
Priority to UA97052129A priority patent/UA65522C2/uk
Publication of ITMI942097A1 publication Critical patent/ITMI942097A1/it
Priority to NO19971624A priority patent/NO320494B1/no
Application granted granted Critical
Publication of IT1270662B publication Critical patent/IT1270662B/it
Priority to US08/910,733 priority patent/US5837495A/en
Priority to US08/910,884 priority patent/US5981713A/en
Priority to HK06103612.6A priority patent/HK1081124B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)

Abstract

Viene descritto un nuovo antagonista dell'interleuchina 1 attivo sia contro la IL-l? e la IL-1?, una nuova sequenza di DNA che codifica per l'antagonista della IL-1 e il metodo per l'ottenimento di un antagonista della IL-1 attraverso la tecnica del DNA ricombinante. Inoltre vengono descritti gli impieghi profilattici, terapeutici e diagnostici del nuovo antagonista della IL-1 in patologie derivanti dalla produzione di IL-1.
ITMI942097A 1994-10-13 1994-10-13 Antagonista della interleuchina-1 IT1270662B (it)

Priority Applications (25)

Application Number Priority Date Filing Date Title
ITMI942097A IT1270662B (it) 1994-10-13 1994-10-13 Antagonista della interleuchina-1
US08/476,860 US5739282A (en) 1994-10-13 1995-06-07 Interleukin-1 antagonist
DK95936482T DK0786002T3 (da) 1994-10-13 1995-10-12 Intracellulær isoform af interleukin-1-receptorantagonisten
KR1019970701931A KR100237936B1 (ko) 1994-10-13 1995-10-12 인터루킨-1 길항제
CNB951956647A CN1224707C (zh) 1994-10-13 1995-10-12 白细胞介素－1受体拮抗剂的细胞内同种型
AT95936482T ATE303439T1 (de) 1994-10-13 1995-10-12 Intrazelluläre isoform von interleukin-1 rezeptor antagonist
CNB200510053993XA CN100363053C (zh) 1994-10-13 1995-10-12 白细胞介素-1受体拮抗剂的细胞内同种型
RU97107461/13A RU2193064C2 (ru) 1994-10-13 1995-10-12 Внутриклеточная изоформа антагониста рецептора интерлейкина-1
HK98101565.6A HK1002659B (en) 1994-10-13 1995-10-12 Intracellular isoform of the interleukin-1 receptor antagonist
CA002202470A CA2202470C (en) 1994-10-13 1995-10-12 Intracellular isoform of the interleukin-1-receptor antagonist
DE69534419T DE69534419T2 (de) 1994-10-13 1995-10-12 Intrazelluläre isoform von interleukin-1 rezeptor antagonist
JP8512932A JPH10509306A (ja) 1994-10-13 1995-10-12 インターロイキン−１レセプターアンタゴニストの細胞内イソ形態
AU38417/95A AU701471C (en) 1994-10-13 1995-10-12 Interleukin-1 antagonist
ES95936482T ES2243942T3 (es) 1994-10-13 1995-10-12 Isoforma intracelular del antagonista del receptor de la interleuquina.
EP95936482A EP0786002B1 (en) 1994-10-13 1995-10-12 Intracellular isoform of the interleukin-1 receptor antagonist
PCT/EP1995/004023 WO1996012022A1 (en) 1994-10-13 1995-10-12 Intracellular isoform of the interleukin-1 receptor antagonist
PT95936482T PT786002E (pt) 1994-10-13 1995-10-12 Isoforma intracelular do antagonista do receptor da interleuquina-1
MX9702616A MX9702616A (es) 1994-10-13 1995-10-12 Isoforma intracelular del antagonista receptor de interleucina -1.
EE9700090A EE03697B1 (et) 1994-10-13 1995-10-12 Interleukiin-1 retseptori antagonisti intratsellulaarne isovorm
BR9509317A BR9509317A (pt) 1994-10-13 1995-10-12 Antagonista a interleucina-1
UA97052129A UA65522C2 (en) 1994-10-13 1995-12-10 Inner cellular isoform of interleukin-1 receptor antagonist
NO19971624A NO320494B1 (no) 1994-10-13 1997-04-09 Renset protein med antagonistisk aktivitet mot minst en av forbindelsene valgt fra gruppen bestaende av interleukin-1-a og interleikun-1-b, isolert DNA sekvens, vektor, vertscelle, og fremgangsmater og anvendelser derav.
US08/910,733 US5837495A (en) 1994-10-13 1997-08-13 DNA encoding interleukin-1 antagonist
US08/910,884 US5981713A (en) 1994-10-13 1997-08-13 Antibodies to intereleukin-1 antagonists
HK06103612.6A HK1081124B (en) 1994-10-13 2006-03-22 Intracellular isoform of the interleukin-1 receptor antagonist

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI942097A IT1270662B (it) 1994-10-13 1994-10-13 Antagonista della interleuchina-1

Publications (3)

Publication Number Publication Date
ITMI942097A0 ITMI942097A0 (it) 1994-10-13
ITMI942097A1 ITMI942097A1 (it) 1996-04-13
IT1270662B true IT1270662B (it) 1997-05-07

Family

ID=11369705

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI942097A IT1270662B (it) 1994-10-13 1994-10-13 Antagonista della interleuchina-1

Country Status (18)

Country Link
US (1) US5739282A (it)
EP (1) EP0786002B1 (it)
JP (1) JPH10509306A (it)
KR (1) KR100237936B1 (it)
CN (2) CN100363053C (it)
AT (1) ATE303439T1 (it)
BR (1) BR9509317A (it)
CA (1) CA2202470C (it)
DE (1) DE69534419T2 (it)
EE (1) EE03697B1 (it)
ES (1) ES2243942T3 (it)
IT (1) IT1270662B (it)
MX (1) MX9702616A (it)
NO (1) NO320494B1 (it)
PT (1) PT786002E (it)
RU (1) RU2193064C2 (it)
UA (1) UA65522C2 (it)
WO (1) WO1996012022A1 (it)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5075222A (en) * 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5872095A (en) * 1990-05-01 1999-02-16 Chiron Corporation IL-1 receptor antagonists medicaments
EP0938500B1 (en) * 1996-10-31 2004-09-22 Applied Research Systems ARS Holding N.V. INTERLEUKIN-1beta-CONVERTING ENZYME (ICE) INHIBITING PEPTIDES
CA2273852C (en) * 1996-12-06 2009-09-29 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
IL126562A0 (en) * 1998-10-14 1999-08-17 Interpharm Lab Ltd Expression and secretion of icil-1 receptor antagonist type ii
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US7166712B2 (en) * 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
WO2006014444A1 (en) 2004-07-06 2006-02-09 Zymogenetics, Inc. Pharmaceutical composition comprising fgf18 and il-1 antagonist and method of use
RU2326947C2 (ru) * 2004-11-23 2008-06-20 Общество с ограниченной ответственностью "ЦИТОКИН" Способ получения рекомбинантного антагониста рецептора интерлейкина-1 человека "арил"
CA2637166A1 (en) * 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
US8323635B2 (en) 2007-11-14 2012-12-04 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
CN101690801B (zh) 2009-10-26 2012-08-01 上海交通大学 白细胞介素-1受体拮抗剂的用途及其药物组合物
EP2686431B1 (en) 2011-03-14 2016-08-03 Phlogo ApS Antagonists of the interleukin- 1 receptor
US9156897B2 (en) 2012-06-08 2015-10-13 Alkermes, Inc. Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
WO2015191783A2 (en) 2014-06-10 2015-12-17 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
CA3119294A1 (en) * 2018-11-15 2020-05-22 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of inflammatory bowel disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0148009B1 (ko) * 1988-05-27 1998-08-01 그래고리 비. 아보트 인터루킨-1 억제제
HK1006856A1 (en) * 1989-11-29 1999-03-19 Amgen Inc. Production of recombinant human interleukin-1 inhibitor
AU649245B2 (en) * 1990-04-02 1994-05-19 Amgen, Inc. Methods for treating interleukin-1 mediated diseases
WO1991017184A1 (en) * 1990-04-27 1991-11-14 The Upjohn Company Modified interleukin-1 inhibitors
JPH05506986A (ja) * 1990-05-01 1993-10-14 カイロン　コーポレイション インターロイキン―１拮抗物質及びその利用

Also Published As

Publication number Publication date
CN1224707C (zh) 2005-10-26
NO320494B1 (no) 2005-12-12
KR970706391A (ko) 1997-11-03
ITMI942097A1 (it) 1996-04-13
EE9700090A (et) 1997-10-15
WO1996012022A1 (en) 1996-04-25
RU2193064C2 (ru) 2002-11-20
AU701471B2 (en) 1999-01-28
CN1679919A (zh) 2005-10-12
BR9509317A (pt) 1997-10-14
CN100363053C (zh) 2008-01-23
NO971624L (no) 1997-05-30
KR100237936B1 (ko) 2000-01-15
EE03697B1 (et) 2002-04-15
CA2202470A1 (en) 1996-04-25
CA2202470C (en) 2008-09-16
PT786002E (pt) 2005-11-30
DE69534419D1 (de) 2005-10-06
HK1002659A1 (en) 1998-09-11
UA65522C2 (en) 2004-04-15
ATE303439T1 (de) 2005-09-15
EP0786002A1 (en) 1997-07-30
MX9702616A (es) 1998-04-30
JPH10509306A (ja) 1998-09-14
HK1081124A1 (zh) 2006-05-12
US5739282A (en) 1998-04-14
CN1161058A (zh) 1997-10-01
ES2243942T3 (es) 2005-12-01
NO971624D0 (no) 1997-04-09
EP0786002B1 (en) 2005-08-31
DE69534419T2 (de) 2006-06-14
ITMI942097A0 (it) 1994-10-13
AU3841795A (en) 1996-05-06

Similar Documents

Publication Publication Date Title
BR9509317A (pt) Antagonista a interleucina-1
ES8706726A1 (es) Un metodo de purificar activador de plasminogeno de tejido uterino
ATE396205T1 (de) Die verwendung von peptiden von il-2 und peptid- derivaten als therapeutische wirkstoffe
IL138665A0 (en) Peptide factor
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
IT1263004B (it) Impiego della l-carnitina e acil l-carnitine nel trattamento a lungo termine di pazienti diabetici non insulino-dipendenti.
DE3587669D1 (de) Menschliche IL-1-cDNS-Sequenzen die für biologisch aktive menschliche IL-1-Proteine kodieren.
IT8121692A0 (it) Procedimento per la regolazione della posizione di almeno un elettrodo di saldatura o brasatura, dispositivo di alimentazione per la sua realizzazione nonche'impiego del procedimento e del dispositivo.
NO922456D0 (no) Bcrf1-proteiner som inhibitorer av interferon-gamma
FI922428A0 (fi) Nya 2-amino-5-cyan-1,4- dihydropyridiner, foerfarande foer deras framstaellning och deras anvaendning i laekemedel.
DE50204475D1 (de) Präparationen von vitamin e in kombination mit afamin
SE9501362L (sv) Smalbandigt integrerat applikationsnät med multifunktionalitet
IT1247527B (it) Agente antiarteriosclerotico, sua preparazione ed uso
FI944907A0 (fi) Uusi antineoplastinen sytokiini
MXPA03010380A (es) Uso de inhibidores de la proteasa para el virus de inmunodeficiencia humana (vih) para bloquear la migracion y/o invasion de celulas, infiltracion de tejido y formacion de edema.
IT1245690B (it) Metodo per produrre complessi di modelli di espanso
FR2694188B3 (fr) Chaise pour bloc dentaire.
IT8021753A0 (it) Procedimento per ottenere farina di soia gradevole al palato, pronta per l'uso umano e prodotto ottenuto.
IT1272995B (it) Procedimento migliorato per la preparazione della 14b-idrossi-etianaldeide.
WO2001075037A3 (fr) Nouveau polypeptide, dihydroorotase humaine 40, et polynucleotide codant pour ce polypeptide
FR2832155B1 (fr) Anticorps stimulant la production d'il-1ra
IT8920060A0 (it) Impianto per la riduzione di pressione del gas metano tra le centrali di pompaggio e le reti di distribuzione all'utenza.
DK0904352T3 (da) Cellelinie
WO2001046243A3 (fr) Nouveau polypeptide, proteine annulaire 8, et polynucleotide codant pour ce polypeptide
IT1230327B (it) Dispositivo per la determinazione della regolazione di altezza ottimale dello schienale di una sedia per ufficio, in funzione della statura dell'utilizzatore.

Legal Events

Date Code Title Description
0001 Granted
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971030